Expiration Date: August 31, 2017
Media: Internet - based
This activity consists of a series of interactive clinical vignettes, short video interviews of leading lung cancer experts, and short summaries of clinical data related to these issues. The video interviews address decision points in the clinical vignettes as well as questions commonly faced in the community oncology practice setting. The content and interviews are related to presentations given at Choosing Therapies for Patients With EGFR-Mutant Lung Cancers: More Options…More Decisions…Better Outcomes, a CME-certified, ancillary satellite symposium held in Chicago, Illinois.
Instructions For This Activity & Receiving Credit
This educational activity is directed toward medical oncologists who treat patients with lung cancer. Nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other healthcare professionals interested in the treatment of cancer also are invited to participate.
- At the conclusion of this activity, you should be better prepared to:
- Explain clinical decision making concerning methods to personalize care in the frontline setting of EGFR-mutated advanced NSCLC
- Discuss emerging technologies and key clinical considerations in the use of rebiopsy or liquid biopsies as methods to identify actionable mutations in lung cancer
- Describe current and emerging strategies to address the problem of acquired resistance to EGFR tyrosine kinase inhibitors in patients with relapsed disease
- Apply current and emerging clinical trial data to manage patients with EGFR-mutated NSCLC along the disease continuum and in consideration of managing central nervous system metastases and adverse-event profiles
Faculty, Staff, and Planners’ Disclosures
Mark G. Kris, MD
Attending Physician, Thoracic Oncology
William and Joy Ruane Chair in Thoracic Oncology
Lead Physician, IBM Watson Collaboration
Memorial Sloan Kettering Cancer Center
Professor of Medicine, Weill Cornell Medicine
New York, NY
Disclosure: Grant/ Research Support: Genentech, Roche; Consultant: Genentech, Roche, Ariad Pharmaceuticals.
Pasi A. Jänne, MD, PhD
Director, Lowe Center for Thoracic Oncology
Dana-Farber Cancer Institute
Scientific Director, Belfer Institute for Applied Cancer Science
Professor of Medicine, Harvard Medical School
Disclosure: Grant/Research Support: AstraZeneca, Astellas Pharma; Consultant: AstraZeneca, Boehringer Ingelheim, Roche, Chugai, Merrimack, Pfizer, Ariad Pharmaceuticals; Stock/Shareholder: Gatekeeper Pharmaceuticals; Other Support: Postmarketing royalties on DFCI-owned patent on EGFR mutations licensed to Lab Corp.
Karen L. Reckamp, MD, MS
City of Hope Comprehensive Cancer Center
Beckman Research Institute
Disclosure: Grant/ Research Support: Ariad Pharmaceuticals, Bristol-Myers Squibb, Boehringer Ingelheim, Clovis Oncology, Eisai; Amgen, Ariad Pharmaceuticals, Astellas Pharma, Nektar, Stemcentrx, Novartis, Pfizer, Xcovery, Adaptimmune, MedImmune; Consultant: Amgen, Ariad Pharmaceuticals, Astellas Pharma, Boehringer Ingelheim, Nektar.
Helena A. Yu, MD
Assistant Attending Physician
Memorial Sloan Kettering Cancer Center
New York, NY
Disclosure: Grant/Research Support: Astellas Pharma, AstraZeneca, Clovis Oncology, Pfizer; Consultant: AstraZeneca.
The following individuals have no relevant financial relationships with commercial interests:
The staff of Physicians’ Education Resource®, LLC.
Disclosure Policy and Resolution of Conflicts of Interest (COI)
As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships, in any amount, occurring within the past 12 months that create a COI.
Additionally, PER® is required by ACCME to resolve all COI. We have identified and resolved all COI prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This CME/CE activity may or may not discuss investigational, unapproved, or off-label uses of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME/CE activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician or nurse relative to diagnostic, treatment, or management options for a specific patient’s medical condition.
The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of Physicians’ Education Resource®, LLC, or any of the companies that provided commercial support for this activity.
Requirements for Successful Completion
- Once you begin the activity, please answer the demographic questions. This will allow you to proceed to the activity.
- This activity contains one or more interactive questions. You may move forward through the activity; however, you may not go back to change answers or review content until you finish the activity.
- At the end of the activity, an “educational content” link will be available for you to download content in PDF format for your reference.
- If you close the Web browser after you complete the activity, the “educational content” link will disappear and you will need to review the activity in its entirety to once again access the link to the “educational content.”
- In order to receive a CME/CE certificate, participants must complete the activity.
Click on the “Request Credits” link at the end of the activity. Complete the posttest and pass with a score of 70% or higher, complete the evaluation, and then click on request for credit. Participants may immediately download a CME/CE certificate upon completion of these steps.
CME Provider Contact Information
Physicians’ Education Resource, LLC
666 Plainsboro Road, Suite 356
Plainsboro, NJ 08536
Toll Free: 888-949-0045
Hardware And Software Requirements
Internet Explorer v.7 or greater (for Windows) | Mozilla Firefox v.2 or greater (for Windows, Mac, Linux)
Minimum System Requirements (Windows)
- A Pentium-based PC or compatible computer
- At least 64MB of RAM
- Windows 95/98/NT/ME/2000/XP/Vista system software
- Screen resolution of 1024 x 786 or larger recommended
- PDF Reader: Adobe Reader 5.0 or higher, Foxit Reader 2.0 or likewise